HAWK Biosystems

Our patented QF-Pro® technology allows us to analyse patient cancer samples and predict which patients will response to cancer immunotherapies.

[Parque Científico UMH @PcientificoUMH]

➡ La empresa @HawkBiosystems colabora con distribuidoras internacionales para impulsar la comercialización de su tecnología dirigida al ámbito oncológico. 📊

Noticia completa 📌:
https://t.co/Xiw7WzJQJO

[Asociación RUVID @asociacionruvid]

🌍 Hawk Biosystems colabora con distribuidoras internacionales de Japón, Tailandia, Reino Unido, Irlanda, República Checa, Eslovaquia, Hungría o Portugal para comercializar su tecnología dirigida al ámbito oncológico https://t.co/2zaXSA82Gd

[APTE @APTE_es]

🌍 La spin-off @HawkBiosystems del @PcientificoUMH firma acuerdos internacionales para llevar su tecnología oncológica QF-Pro a Japón, Tailandia, UK y más. 🎯🔬 

https://t.co/Teg8xu3pfA

#LosParquesAportan #Biotecnología #Salud #Oncología

[HAWK Biosystems @HawkBiosystems]

We are reshaping treatment strategies and advancing personalised medicine at an unprecedented resolution. Don't miss out on this insightful presentation! Reach out to us to secure a meeting with Fernando Aguirre and Veronique Calleja! See you at #Immuno24! 🌟 #OGImmuno

[HAWK Biosystems @HawkBiosystems]

🔬We're thrilled to announce that our CSO, Veronique Calleja, PhD, will be presenting at Immuno UK 2024 on April 25th at 14:10 in London, United Kingdom. @OGConferences #OGImmuno #Immuno24

[HAWK Biosystems @HawkBiosystems]

🔍 Veronique will dive into how our innovative QF-Pro® technology is revolutionising cancer immunotherapy. By precisely measuring PD-1/PD-L1 interaction in NSCLC tumour samples, we can triple response rates and double overall survival rates in lung cancer. #OGImmuno #Immuno24

[HAWK Biosystems @HawkBiosystems]

https://t.co/d3wMqOfswJ

[HAWK Biosystems @HawkBiosystems]

Esta semana, nuestro CEO, Fernando Aguirre, se sentó con @ondavasca para una entrevista. Nuestra plataforma de bioimagen de última generación, QF-Pro® ofrece un enfoque innovador al analizar las funciones de las proteínas en biopsias de pacientes con una precisión sin precedentes

[HAWK Biosystems @HawkBiosystems]

Nuestro objetivo es ayudar en la lucha contra el cáncer, identificando aquellos pacientes que responderán mejor a las inmunoterapias.
¡No te pierdas la oportunidad de escuchar esta entrevista y descubrir cómo Hawk Biosystems está contribuyendo al tratamiento del cáncer!

[HAWK Biosystems @HawkBiosystems]

Beyond NSCLC, QF-Pro® technology:🌟 Measures diverse functional interactions and post-translational modifications. 🔬 Unveils new cancer treatment biomarkers and diagnostics. This breakthrough shifts the paradigm, offering personalized treatments and life-saving opportunities.

[HAWK Biosystems @HawkBiosystems]

🔬 **Unlocking Precision Medicine for NSCLC: QF-Pro® Breakthrough** 🔬 The PD-1/PD-L1 pathway in NSCLC holds immense potential, but relying solely on high PD-L1 scores for treatments misses the mark for 60% of patients.

[HAWK Biosystems @HawkBiosystems]

**Key Findings:**🎯 PD-1/PD-L1 engagement predicts treatment response and survival in NSCLC.🔍 25% of potential IO-treated NSCLC patients are currently overlooked.

[HAWK Biosystems @HawkBiosystems]

🎉 Happy New Year from the HAWK Biosystems team! May the year ahead be filled with good health, prosperity, and groundbreaking scientific discoveries. Here's to a fantastic year ahead!

[HAWK Biosystems @HawkBiosystems]

Exciting times at @HawkBiosystems! Recently, our team came together to share our strategy and vision for the future. It was a session fueled by innovation, teamwork, and a strong dedication to doing a great work. Here's to the continued journey of innovation and teamwork! 🦅

[HAWK Biosystems @HawkBiosystems]

Beyond the inspiring talks from the many prominent scientists and medics whose work has revolutionised cancer research, this meeting was a fantastic opportunity for the exchange of ideas and to opening the doors to interdisciplinary and translational collaborations.”

[HAWK Biosystems @HawkBiosystems]

Last week, our team had the opportunity to participate in the @ASEICAnews 40th Congress. ASEICA, the Spanish Association for Cancer research, brings together leading basic and clinical researchers in oncology in the country, promoting cancer research and scientific outreach.

[HAWK Biosystems @HawkBiosystems]

Our CSO, Veronique Calleja, and Scientific Officer, Cristina Cacho, were privileged to be part of this event. Veronique shared her enthusiasm about the event, remarking, “It was great to be part of this amazing celebration of the 40th anniversary of ASEICA in A Coruña.

[HAWK Biosystems @HawkBiosystems]

🔬 Exciting News! From November 14th to 16th, CSO, Veronique Calleja (PhD), and Scientific Officer, Cristina Cacho (PhD), will be attending the 40th-anniversary congress of ASEICA. 🎉We are looking forward to see you there! #ASEICACongress #CancerResearch #ScienceInAction

[ASEICA @ASEICAnews]

🛑Science goes far beyond the lab!

📢Are you ready to hear some helpful career-related advice from our topline speakers?

📍MEET THE EXPERT
40th Anniversary #ASEICACongress

‼️ CONGRESS ATTENDANTS NEED TO REGISTER FOR THESE SESSIONS

📅14 Nov
⏰18:30

ℹ️https://t.co/t1NDBlHLRu

[HAWK Biosystems @HawkBiosystems]

En este Día Mundial contra el Cáncer de Mama, @HawkBiosystems se une a la causa y se tiñe de rosa en apoyo a todas las valientes personas que han enfrentado y continúan combatiendo esta enfermedad. Juntos, unidos contra el cáncer. 💗🎗 #DiaMundialContraElCancerDeMama